AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 292 min read$BEAM

FMR LLC sold $10.0M of BEAM (indirect holdings)

FMR LLC sold 284,860 indirectly-held shares of Beam Therapeutics Inc. (BEAM) at an average of $35.24 ($35.12–$35.26, $10.04M total) across 2 trades over 2026-06-25 to 2026-06-26.

Original reporting
SEC EDGAR · FMR LLC
Published Jun 29, 2026, 6:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BEAM
Bearish
medium confidence
Mentioned
$BEAM
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BEAMBearishLow
01

Why it matters

Traders may treat this as a modest negative sentiment input for BEAM, but it does not introduce new clinical, regulatory, or financial guidance.

02

Market read

A fresh $10.04M open-market sale by a 10% owner is disclosed today, which can influence short-term positioning and sentiment around BEAM.

03

What to watch

No 10b5-1 plan is indicated; however, the transactions occurred over two days (6/25–6/26) and the filing alone doesn’t confirm intent or future selling pace.

Relevance 7/10Novelty 6/10Timing: today’s SEC Form 4 filing (filed 2026-06-29)

Background

The article is an SEC Form 4 insider transaction disclosure: FMR LLC (a 10% owner) sold Beam Therapeutics shares indirectly via open-market sales.

Company-level read

Ticker impact

$BEAMBearishMedium confidence
Context

FMR LLC filed a Form 4 selling 284,860 Beam Therapeutics shares in open-market transactions totaling about $10.04M.

Expected impact

Near-term sentiment could soften; magnitude likely limited because it’s an SEC Form 4 sale without accompanying fundamental news.

Evidence & confidence

This is a primary-source transaction print (new today) with clear size ($10.04M) and role (10% owner), but it lacks a stated reason, 10b5-1 plan, or linkage to operational updates.

Market effects

Sector

Limited read-through to biotech broadly; this is a single-company ownership transaction without sector-wide catalyst.

Regional

No clear regional spillover indicated by the filing details.

Global

Minimal global relevance; transaction is specific to Beam Therapeutics holdings.

Counterpoint

What could challenge this read

The sale could be routine liquidity management rather than a bearish view, especially since the filing does not provide a thesis or link to performance.

Key entities

  • public_company
    Beam Therapeutics Inc.

    Issuer of the Form 4; subject of the reported insider sale.

  • insider_entity
    FMR LLC

    Reporter; 10% owner conducting indirect open-market sales.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BEAM insider trading history →

Related articles

AUG 21
$BEAMMed

Beam Global Q2 2026 Earnings Call Summary

Beam Global reported a 174% sequential revenue increase in Q2 2026, driven by backlog conversions. The company diversified into global energy, mobility, and intelligence sectors, with Europe matching U.S. revenue. Battery business gained traction in drones, robotics, and defense. Yuma relocation cut costs. Management expects margin expansion, targets AI data centers, and focuses on recurring revenue models. The company remains debt-free with a $100M credit line. Q2 gross margin improved by 30 pe

yahoo.com3 min
AUG 5
$BEAMMed

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

Beam Therapeutics (BEAM) reported a wider-than-expected Q2 2026 loss of $1.18 per share versus a $1.00 consensus loss. Revenue fell to $0.5 million, below a $30 million estimate, from $8.5 million a year earlier. Cash and securities were about $1.2 billion, supporting operations into mid-2029. Pipeline updates include risto-cel and BEAM-302 accelerated-approval plans.

finance.yahoo.com6 min
AUG 4
$BEAMMed

Beam Therapeutics Inc. (BEAM): Results of Operations and Financial Condition

Beam Therapeutics Inc. (BEAM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation

SEC EDGAR 8-K4 min
JUL 8
$BEAMMedAI 8/10

Why is Beam Therapeutics stock sliding today? By Investing.com

Beam Therapeutics shares fell about 5% after an arbitration tribunal ruled for Prime Medicine in a dispute over rights to PM647, an investigational gene editing therapy for Alpha-1 Antitrypsin Deficiency. The tribunal said PM647 is within Prime’s licensed “Field” under a 2019 agreement. The move followed a recent 52-week high and an H.C. Wainwright Buy rating with an $80 target, while broader equities declined on renewed geopolitical risk.

investing.com3 min